Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to assess the effect of a new PPARgamma modulator on the expression and activity of the lactase enzyme in human intestinal epithelial cells. Based on their previous experimental results, the investigators hypothesized that modulating intestinal PPARgamma activity is a new pharmacological mechanism allowing the control of lactase expression and activity in the gut

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Lille
• Collaborators: French National Society of Gastroenterology; French society of Gastroenterology; Institut National de la Santé Et de la Recherche Médicale, France

Criteria

Inclusion Criteria:

• Subjects undergoing gastroduodenal endoscopy for digestive cancer screening

• Subjects undergoing gastroduodenal endoscopy for ulcerative gastroduodenal diseases

• Subjects undergoing gastroduodenal endoscopy for epigastric pains

• Subjects undergoing gastroduodenal endoscopy for gastroesophageal reflux diseases

Exclusion Criteria:

• Subjects with macroscopic duodenal lesions detected at endoscopy

• Subjects suffering from coeliac disease

• Subjects suffering from atrophic gastritis

• Subjects who use anticoagulant

• Pregnancy or breast feeding